EMA Updates Flu Vaccine Recommendations

Article

The agency updated its list of recommended influenza virus strains that manufacturers should include in vaccines for the autumn 2019 season.

On May 20, 2019, the European Medicines Agency (EMA) announced that it updated the European Union list of recommendations for the influenza virus strains that manufacturers should include in vaccines for the prevention of seasonal influenza starting in autumn 2019.

The recommendations contain a decision on suitable H1N1 and H3N2 viruses for seasonal live attenuated influenza vaccines (LAIV). The list of reagents for vaccine standardization has also been updated.

Details such as the specific virus strains to be included are available in the updated 2019/2020 recommendations, which were issued by EMA's Biologics Working Party ad-hoc Influenza Working Group. The ad-hoc Influenza Working Group initially made recommendations for the 2019/2020 flu vaccines on April 1, 2019 and first updated its recommendations on April 10, 2019. The list is developed on the basis of recommendations by the World Health Organization.

Applications to change the composition of centrally authorized flu vaccines are due by June 17, 2019.

Source: EMA

Recent Videos
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Adam Sherlock, CEO of Qinecsa Solutions
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
© 2025 MJH Life Sciences

All rights reserved.